DSIP, the delta sleep-inducing peptide sold as emideltide, is not FDA approved and is not on the list of substances US pharmacies may compound. On 24 July 2026 an FDA advisory committee voted against listing it, 6 to 7, the only peptide of seven it turned down. The HHS draft policy of 30 October 2026 leaves it out.

The short version. DSIP, sold as emideltide, is not FDA approved and is not on the 503A Bulks List. FDA staff recommended against listing it, and on 24 July 2026 the advisory committee agreed, 6 to 7. The HHS draft policy of 30 October 2026 covers six other peptides and not this one. Every human study gave it into a vein.
DSIP, short for delta sleep-inducing peptide and sold under the common name emideltide, is a chain of nine amino acids. The FDA briefing document prepared for the July 2026 Pharmacy Compounding Advisory Committee records that it was first reported in 1963, by Monnier, in the cerebral venous blood of rabbits, and was synthesised in 1976. Its name comes from the delta rhythm, the slow brain waves of deep sleep, which the peptide increased in early experiments. The FDA notes that its sleep effects in animals appear to run through the body's own opioid system: DSIP does not seem to bind opioid receptors directly, but it can trigger the release of endorphins, and that same mechanism is why researchers tested it for drug and alcohol withdrawal.
Emideltide is not a United States Adopted Name or an international nonproprietary name, and the FDA flagged that as a safety issue in itself: suppliers sell several salts and derivatives under the same label, so a patient may get a different substance from the one a doctor ordered. Two nominations, from Wells Pharmacy Network and LDT Health Solutions, did not make clear whether they meant the free base or the acetate salt, so the agency evaluated both after the nominations were withdrawn. Online, the FDA found DSIP marketed by integrative neurology clinics, concierge services, medical spas, wellness clinics and online retailers as injections and nasal sprays for sleep, stress, pain, cancer, Alzheimer's and Parkinson's disease, and detoxification.

In plain EnglishDSIP is a small peptide named after deep sleep. It was found in rabbits in the 1960s and tested on small groups of people in the 1980s. Today it is sold online for sleep and stress. In the US it is not an approved drug.
DSIP's legal position rests on four dated facts, and on this compound all four point the same way. First, the FDA briefing states that neither emideltide free base nor emideltide acetate is a component of an FDA approved drug, and neither has a USP or National Formulary monograph. Second, emideltide is not on the 503A Bulks List, and no proposed or final rule has added it; the Federal Register returned no document mentioning emideltide since 1 July 2026 when we checked on 17 November 2026. Third, McDermott Will & Schulte reported that HHS confirmed emideltide's removal from Category 2 on 15 April 2026 after the nominations were withdrawn, which is not the same as entering Category 1. Fourth, the committee voted against it in July and HHS left it out in October.
| Question | What the record says | Source |
|---|---|---|
| FDA approved product? | None. Not a component of any approved drug | FDA briefing, PCAC July 2026 |
| On the 503A Bulks List? | No | No proposed or final rule |
| FDA staff view | Balance of criteria weighs against listing | FDA briefing memo, 11 May 2026 |
| Advisory committee | Against: 6 for, 7 against, 1 abstention | McDermott, 27 Jul 2026 |
| HHS draft policy | Not covered. Six other peptides are | FR Doc. 2026-22192, 30 Oct 2026; BakerHostetler, 28 Oct 2026 |
| Studies by the nominated route? | None. Every human study was intravenous | FDA briefing, PCAC July 2026 |
The HHS notice, FR Doc. 2026-22192, says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide listed in its Appendix A, while FDA develops the 503A list through rulemaking. BakerHostetler, in its summary of 28 October 2026, lists those peptides as BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c, each with permitted routes. Emideltide is absent, which matches the vote: HHS cited the committee meetings as the basis for the policy, and DSIP is the one peptide the committee did not recommend. The notice also calls the policy a draft that is not binding on HHS or the public.

In plain EnglishSeven peptides went to the FDA committee in July 2026. Six got a yes and then a draft HHS promise not to go after pharmacies making them. DSIP got a no, and it has no such promise. None of this is an approval for any of the seven.
DSIP is sold today as an injection under the skin. The FDA found no study of it given that way, and the committee that backed six other peptides voted this one down.
The vote is the fact most often left out of pages that rank for DSIP. On 24 July 2026, the second day of the meeting, the committee considered emideltide for opioid withdrawal, chronic insomnia and narcolepsy and voted 6 in favour, 7 against and 1 abstention, according to McDermott Will & Schulte, which tabulated every vote of the two days. The same committee had backed BPC-157, KPV, TB-500 and MOTS-c the day before, often against its own FDA staff, and backed Epitalon and Semax the same day. The Ozemback peptide legal status tracker carries emideltide in its own "recommended against" group, with the date of each fact. For how the committee handled the other six, see our analysis of the vote, or try the approved, recommended or neither quiz.
The FDA's conclusion: insufficient information on effectiveness for chronic insomnia, narcolepsy and opioid withdrawal when given into a vein, and no data at all for the injection under the skin that was nominated.

The insomnia record is a handful of small studies from the 1980s and early 1990s. Schneider-Helmert and Schoenenberger in 1981 gave DSIP or placebo into a vein to six middle-aged people with chronic insomnia in a crossover design and reported fewer interruptions in sleep, but no change in how fast they fell asleep. The largest placebo-controlled trial the FDA reviewed, Bes and colleagues in 1992, followed 16 people with chronic insomnia in a sleep laboratory for five nights and found no significant difference from placebo in objective sleep measures or subjective sleep quality; the authors themselves wrote that the peptide showed at best some weak effects. The FDA called the insomnia studies inconclusive and at best preliminary, citing poor control groups, small samples and inconsistent results between authors.
The narcolepsy evidence is a single case report: one 35-year-old man studied by Schneider-Helmert in 1984. The withdrawal evidence is open label. Dick and colleagues in 1984 treated 107 people in withdrawal from alcohol or opioids at a Geneva psychiatric hospital, 60 of them opioid users, and reported fewer withdrawal signs in those assessed, with no control group. Backmund and colleagues in 1998 treated seven people in opioid withdrawal and found that only two completed the schedule, both of whom needed another drug for insomnia on day three; the authors called DSIP's role an open question. The FDA notes that clinical guidelines on insomnia, narcolepsy and opioid withdrawal do not mention DSIP, and that FDA approved treatments with established efficacy exist for all three.
In plain EnglishA few small studies, most of them decades old, gave DSIP into a vein. The best-controlled one, 16 people with insomnia, found no real difference from a dummy injection. Nobody has studied the shot under the skin that is sold today.
The FDA's safety conclusion is that the safety of DSIP products is insufficiently characterised. Across the studies it reviewed, 209 people received the peptide into a vein for 1 to 15 days. Insomnia studies reported no significant adverse effects, but in the 1984 withdrawal study nine of 107 patients had transient sweating, headache, nausea or vertigo, and three had serious reactions, two with low blood pressure at the first injection and one described as progressive after a second. The FDA's FAERS search through 3 March 2024 returned zero reports, and no outsourcing facility has reported compounding emideltide. Because DSIP releases endorphins, the FDA warned it could have addictive properties, and found no study of its abuse potential. It also flagged immunogenicity and aggregation for an injected nine amino acid peptide, and found no animal toxicity studies to rely on.
There is no FDA approved dose of DSIP, because there is no FDA approved product.
Every DSIP dose figure you will find in the US comes from somewhere other than a US label. The human studies of the 1980s and 1990s gave the peptide into a vein, dosed by body weight, in hospital or sleep laboratory settings, which says nothing about the subcutaneous injections and nasal sprays sold online today. The FDA found no clinical data for injection under the skin and questioned whether the nominated injection could even be made at the stated strength, because the free base dissolves poorly in water and no co-solvent was described. The FDA briefing also cites a Kentucky pharmacy that compounded and distributed emideltide products between October 2018 and April 2020, according to a US Attorney press release. We report this because it is the record, and we do not publish a recommended dose, cycle or protocol for DSIP or any other compound.

Check whether the page mentions the July 2026 vote at all; many DSIP pages describe the peptide wave as if every compound got a yes, and this one got a no. Check whether it says DSIP is covered by the HHS announcement; it is not one of the six. Check whether the sleep claims cite a study with a placebo group, and whether that study gave DSIP into a vein, as all of them did, or the way the page is selling it. Check who pays the author: nearly every site ranking for DSIP benefits or dosage sells it, sells a consultation or links to a seller. This page carries a date at the top, 17 November 2026, so you can tell when it stops being current. Related files: Epitalon, voted the same day for insomnia, and Semax.
DSIP, or emideltide, is not an FDA approved drug and is not on the 503A Bulks List of substances pharmacies may compound. An FDA advisory committee voted against listing it on 24 July 2026, 6 to 7 with one abstention, and the HHS draft enforcement policy of 30 October 2026 does not include it. Whether a specific seller is acting lawfully is a question for a lawyer.
No. Advisory committees do not approve drugs, and this one voted the other way. On 24 July 2026 the Pharmacy Compounding Advisory Committee voted 6 in favour, 7 against and 1 abstention on emideltide for opioid withdrawal, chronic insomnia and narcolepsy, per McDermott Will & Schulte. It was the only one of seven peptides reviewed that week not recommended.
No. The draft policy published in the Federal Register on 30 October 2026, FR Doc. 2026-22192, covers six peptides according to BakerHostetler: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c, each with set routes. Emideltide is not on the list, and the notice says the policy is not binding.
The record does not show it. In the largest placebo-controlled trial the FDA reviewed, 16 people with chronic insomnia in 1992, there was no significant difference from placebo in objective sleep measures or sleep quality. The FDA called the insomnia studies inconclusive and at best preliminary, and found no data at all for injection under the skin.
There is no FDA approved dose, because there is no FDA approved product. The 1980s and 1990s studies gave the peptide into a vein, dosed by body weight, which does not tell you anything about the injections sold today. We do not publish a dose, cycle or protocol for this or any compound.
Insufficiently characterised, in the FDA's words. Insomnia studies reported no significant adverse effects in small groups, while withdrawal studies reported transient headache, nausea and vertigo and cases of low blood pressure, one described as progressive after a second injection. The FDA also flagged a possible risk of addiction that has never been studied.
Yes and no. Emideltide is a common name for the delta sleep-inducing peptide, not an official adopted name, and the FDA evaluated two different substances under it: the free base and the acetate salt. The peptide legal status tracker carries its legal position.
Whatever you decide, your own numbers are the one part of this that is not contested. A baseline panel costs less than a month of most things sold in this category and it is yours to keep.
Ozemback is not a provider and takes no part in any clinical decision. The link above is an affiliate link: if you buy a panel through it we receive a commission at no additional cost to you. We are paid for the referral, never for the result, and it does not change what we publish.